

Electronic Acknowledgement Receipt

EFS ID:	4416468
Application Number:	10699517
International Application Number:	
Confirmation Number:	8113
Title of Invention:	Prevention and treatment of synucleinopathic disease
First Named Inventor/Applicant Name:	Dale B. Schenk
Customer Number:	20350
Filer:	Rosemarie L. Celli/Tina Trieu
Filer Authorized By:	Rosemarie L. Celli
Attorney Docket Number:	015270-008920US
Receipt Date:	08-DEC-2008
Filing Date:	31-OCT-2003
Time Stamp:	18:50:35
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	4138
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		015270-008920US_SID5_12-08-2008.PDF	230662 4c5a899ca2e70d7aea3e1e17230e1c71a0fbae08	yes	5
Multipart Description/PDF files in .zip description					
	Document Description		Start		End
	Information Disclosure Statement Letter		1		3
	Information Disclosure Statement (IDS) Filed (SB/08)		4		5
Warnings:					
Information:					
2	Foreign Reference	222-WO08103472A2.pdf	6759680 2f5870f87b0f72125384941cc6180b8f547a1b9a7	no	135
Warnings:					
Information:					
3	Foreign Reference	235-WO03000714A2.pdf	595533 28071056197742a40ff8e043c123508a0f01632c	no	12
Warnings:					
Information:					
4	Foreign Reference	236-WO03000714A3.pdf	119865 a48fc14ac110587618b6cc08ca2a5aaa0a0a25	no	2
Warnings:					
Information:					
5	Foreign Reference	227-WO0160794A2.pdf	2081191 070b4c579c0b2946c2a33be4906165c0e17af460bb	no	55
Warnings:					
Information:					
6	Foreign Reference	228-WO0160794A3.pdf	136589 85d0c3567d4e5d8bc560230f1e031140f2e9d4c	no	3
Warnings:					
Information:					

7	NPL Documents	226-Anderson/JBC281-40-29739_2006.pdf	2681006 d75c17d4bdc4f96x0081d18c4d91d3c58a	no	14
Warnings:					
Information:					
8	NPL Documents	224-CHILCOTE_ComparisonofalphasynucleinAbstract.pdf	73698 e961e813027b9813c1e18424083f5e013a6801	no	2
Warnings:					
Information:					
9	NPL Documents	237-EP037830083-3_EuroSupplSearch.pdf	407998 417b9c298b627032c1829957d6597b941c06915e	no	11
Warnings:					
Information:					
10	NPL Documents	238-EP05814041-9_SupplEuroSearchReport.pdf	1237320 e88499d3bedc91d4c02bce9f8d22d001a807	no	26
Warnings:					
Information:					
11	NPL Documents	229-Hashimoto_BetaSynucleinInhibitsAlpha.PDF	568920 91e7db791d4d5a15f32c8f2692d733c699801	no	6
Warnings:					
Information:					
12	NPL Documents	233-Heiser_InhibitionofHuntingtinFibrillogenesis_2000.PDF	374433 25c1abde13c5c41625c5465295368e923079e0c4	no	3
Warnings:					
Information:					
13	NPL Documents	232-Lecerf_HumanSingleChainFV_2001.PDF	319915 0c5d8efc9c3da32bee119c7a1d806e63995b9	no	3
Warnings:					
Information:					
14	NPL Documents	225-Lee_TruncatedAlphaAbstract.pdf	32849 58ab9b93d19a9c4918c99d9eebdc542bc9801	no	2
Warnings:					
Information:					
15	NPL Documents	234-Rochet_InhibitionofFibrillization_2000.PDF	446278 772d4c3ab17e4913a0f80c942988c5a0c80f	no	4
Warnings:					
Information:					

16	NPL Documents	223- TofarisJBC278-45-44405_2003. pdf	336461 c594bc2a7226fbedb1e29f0513a91b1c1e 28ce	no	7
Warnings:					
Information:					
17	NPL Documents	231- Wanker_ProtienAggregationin HuntingtonsandParkinsonsDis. 2000.PDF	354183 5a5f4c078a175d907d472becd902519445 e9593	no	3
Warnings:					
Information:					
18	NPL Documents	230- Windsch_DevelopmentOfANe wTreatment_2002.PDF	317607 689b4c4e518fbd45b21f5ac7a8193f0aae 8f14	no	4
Warnings:					
Information:					
19	Fee Worksheet (PTO-06)	fee-info.pdf	30130 5c3b35c0843880215d0e2bb181401c95d8 a1dd	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			17104318		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					